Studies have shown that genetic mutations in IKZF1 are associated with poor prognosis in hematologic tumors and colorectal tumors (39–41); Low expression of DOCK2 is associated with a poor prognosis in colorectal cancer and lung cancer patients (42–44). This evidence concerns the gene IKZF1 and colorectal cancer.